294 results
P
patients with liver lesions
I/C
LI-RADS algorithm, original studies reporting probability of LR-M for HCC and non-HCC malignancy on MRI
O
pooled percentages of HCC and non-HCC malignancy for LR-M, sources of heterogeneity between reported results
P
Hepatocellular carcinomas (HCCs), non-HCC malignancies
I/C
Contrast-enhanced ultrasound (CEUS) Liver Imaging Reporting and Data System category M (LR-M), CEUS LR-M category, Non-HCC malignancies
O
Proportion of CEUS LR-M in HCC and non-HCC malignancies, Frequency of individual CEUS LR-M imaging features
P
Laparoscopic Roux-en-Y gastric bypass, laparoscopic sleeve gastrectomy
I/C
Laparoscopic Roux-en-Y gastric bypass, laparoscopic sleeve gastrectomy, Laparoscopic Roux-en-Y gastric bypass vs. laparoscopic sleeve gastrectomy
O
Excess weight loss, Type 2 diabetes mellitus resolution, Postoperative complication and reoperation rates, Dyslipidemia, Hypertension, Gastroesophageal reflux disease
P
monolithic translucent Y-TZP ceramics
I/C
hydrothermal aging, aged Y-TZP ceramics
O
translucency parameter (TP), L*
P
FTSF, V-Y closure, perforator flap, non-perforator flap
I/C
separately combined full-thickness skin graft (FTSG), FTSG method based on V-Y closure, perforator flap, non-perforator flap
O
adapted FRFF size, postoperative complications
P
morbid obesity patients
I/C
laparoscopic sleeve gastrectomy (LSG), Roux-en-Y laparoscopic gastric bypass (RYLGB)
O
weight loss, resolution of comorbidities, postoperative complications, operative time, hospital stay, and improvement in quality of life
P
patients with advanced cancer
I/C
receiving immune checkpoint inhibitors (ICIs), sarcopenia vs. no sarcopenia
O
response rate, 1-y progression-free survival (PFS) rate, 1-y overall survival (OS) rate, hazard ratios (HRs) of PFS and OS
P
rodents
I/C
unmodified MSC(M), controls
O
mortality rate
P
I/C
V, i, t, a, m, i, n, , D
O
m, u, s, c, l, e, , r, e, c, o, v, e, r, y